Cyclic Glycine-Proline Improves Memory and Reduces Amyloid Plaque Load in APP/PS1 Transgenic Mouse Model of Alzheimer’s Disease

Figure 2

cGP treatment reduces amyloid plaque load in the hippocampus of APP/PS1 mice. Amyloid plaque load was evaluated in the hippocampus of APP/PS1 mice and cGP-treated APP/PS1 (cGP-APP/PS1) mice. Representative thioflavin-S-stained hippocampal sections from both groups of mice are shown in (a) (scale bar, 500 μm). Treatment with cGP reduced the plaque density (b1) and percentage area covered by plaques (b2) in cGP-APP/PS1 mice ( in both groups). The average size of remaining plaques in cGP-APP/PS1 mice was similar to plaque size in APP/PS1 mice (b3), and total area used for plaque load analysis (b4) was similar in the two groups of mice. Asterisks denote significant difference () compared to APP/PS1 group. N.S.: not significant.

(a)

(b)